Arrowhead Research Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold L

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to announce Q1 earnings results on Wednesday, Feb. 2, after market close.

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. Johnson & Johnson (NYSE: JNJ) got the ball rolling on large-cap biopharma earnings, with

Goldman Sachs has launched its coverage on platform biotech companies issuing Buy recommendations for Arvinas <> and Arrowhead Pharmaceuticals <> with 12-month price targets…

Arrowhead has major pharma partners for several potential blockbuster therapies. ARWR's license of ARO-HSD to GSK adds to cash and potential future royalties.

Accumulate Arrowhead For Its RNAi Pipeline

Arrowhead Pharmaceuticals (ARWR) has dosed the first patients in Phase 3 PALISADE study, to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia

Arrowhead Pharmaceuticals Inc. (ARWR) shares closed today at 1.8% above its 52 week low of $57.92, giving the company a market cap of $6B. The stock is currently down 11.1% year-to-date, down 25.8% over the past 12 months, and up 2907.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.4% lower than its 5-day moving average, 12.3% lower than its 20-day moving average, and 12.5% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 63.3% The company's stock price performance over the past 12 months lags the peer average by -278.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Brokerages forecast that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) will report sales of $67.30 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Arrowhead Pharmaceuticals earnings. The lowest sales estimate is $25.00 million and the highest is $150.00 million. Arrowhead Pharmaceuticals posted sales of $21.30 million in the same quarter []

Equities analysts forecast that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) will post $67.30 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Arrowhead Pharmaceuticals earnings, with estimates ranging from $25.00 million to $150.00 million. Arrowhead Pharmaceuticals reported sales of $21.30 million in the same quarter last year, []

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been assigned an average recommendation of Buy from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that []

Related Stocks: ARWR ,

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 60,000 shares of the stock in a transaction dated Wednesday, December 15th. The stock was sold at an average price of $67.56, for a total transaction of $4,053,600.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Christopher Richard []

New York State Teachers Retirement System boosted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,864 shares of the biotechnology companys stock after buying an additional 4,492 shares []